Skip to content
DataLookout
Menu

Roche / Genentech clinical trial pipeline

Get alerts when Roche / Genentech's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-10

What changed in the last 30 days

75 trials changed in the last 30 days: 1 stopped, 21 with notable changes, 53 with minor changes only.

  1. Notable: TARBELA-PD · Effects and Safety of RO7568282 in Early Parkinson's Disease Phase changed: Phase 1/2 → Phase 2 Hoffmann-La RochePhase 2 NCT07781644
  2. Notable: SKYSCRAPER-01 · Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab · Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer Results posted: Nov 9, 2026 Hoffmann-La RochePhase 3 NCT04294810
  3. Minor: KRASCENDO 3 · Divarasib Compared With Investigator's Choice of Immunotherapy or Observation · Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) Trial sites expanded: 46 → 104 locations Hoffmann-La RochePhase 3 NCT07541170
  4. Minor: Enith2 · Enicepatide (RO7795068) · Obesity or Overweight and Type 2 Diabetes Trial sites expanded: 210 → 222 locations Hoffmann-La RochePhase 3 NCT07351058
  5. Minor: Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab · Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Primary and study completion moved earlier from Mar 31, 2027 to Dec 28, 2026 Hoffmann-La RochePhase 1/2 NCT04077723
  6. Minor: OCARINA 3 · New Subcutaneous Formulation of Ocrelizumab · Multiple Sclerosis Primary completion date changed from estimate of Feb 15, 2028 to Sep 1, 2026 Hoffmann-La RochePhase 1 NCT07667322
  7. Notable: TARBELA-AD · Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease Recruitment opened Hoffmann-La RochePhase 2 NCT07781657
  8. Notable: UmbrellaMAX · Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Enrollment increased: 100 → 200 participants Hoffmann-La RochePhase 3 NCT05862285
  9. Minor: IMvigor011 · Atezolizumab Versus Placebo as Adjuvant Therapy · High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy Trial completed Hoffmann-La RochePhase 3 NCT04660344
  10. Minor: HINALEA 1 · Risdiplam Administered as an Early Intervention · Spinal Muscular Atrophy After Gene Therapy Enrollment closed, study ongoing Hoffmann-La RochePhase 4 NCT05861986
  11. Minor: Pertuzumab · Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial Primary and study completion pushed from Dec 31, 2026 to Mar 28, 2027 Hoffmann-La RochePhase 3 NCT02320435
  12. Minor: WILL-EMI NIS · Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment Primary and study completion pushed from Nov 1, 2026 to Jan 18, 2027 Hoffmann-La RocheNot specified NCT06883240
  13. Minor: Sightspire · 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD Trial sites expanded: 61 → 64 locations Hoffmann-La RochePhase 3 NCT06847542
  14. Minor: PrevenTRON · Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease Trial sites expanded: 34 → 72 locations Hoffmann-La RochePhase 3 NCT07717411
  15. Minor: Enicepatide in Generally Healthy Adult Chinese Participants Enrollment closed, study ongoing Hoffmann-La RochePhase 1 NCT07626515
  16. Minor: AMETRINE-PEDS · Afimkibart (RO7790121) · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 26 → 29 locations Hoffmann-La RochePhase 3 NCT07158242
  17. Minor: Krascendo 2 · Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin · Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Trial sites expanded: 288 → 299 locations Hoffmann-La RochePhase 3 NCT06793215
  18. Minor: ZUPREME-3 · Petrelintide · Overweight or Obesity Trial sites expanded: 3 → 8 locations Hoffmann-La RochePhase 3 NCT07843498
  19. Minor: BREnnA · RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine · Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Trial sites expanded: 206 → 219 locations Hoffmann-La RochePhase 2/3 NCT07413939
  20. Minor: Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy · Previously Treated Multiple Myeloma Trial sites expanded: 1 → 5 locations Hoffmann-La RochePhase 2 NCT07825064
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-05 NCT07918846 A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity… Phase 3 Not Yet Recruiting
2026-10-30 NCT07905924 A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or… Phase 1 Not Yet Recruiting
2026-10-22 NCT07889648 A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in… Phase 3 Not Yet Recruiting
2026-10-20 NCT07883577 A Study of RO7821657 in Participants With Solid Tumors Phase 1 Not Yet Recruiting

Active trials by phase

Phase 1
55
Phase 1/2
23
Phase 2
51
Phase 2/3
3
Phase 3
90
Phase 4
9
Not charted: 19 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 49

Get alerts when Roche / Genentech's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free